![](/img/cover-not-exists.png)
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden
O’Day, Ken, Meyer, Kellie, Stafkey-Mailey, Dana, Watson, CrystalVolume:
18
Language:
english
Journal:
Journal of Medical Economics
DOI:
10.3111/13696998.2014.991786
Date:
April, 2015
File:
PDF, 500 KB
english, 2015